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Introduction
Primary malignant tumors of the spine are rare and mainly 
include chordoma, chondrosarcoma, Ewing sarcoma or 
primitive neuroectodermal tumor (PNET), and osteosar-
coma [1]. In patients under 30 years of age, tumors of 
the spine are fairly uncommon and are generally benign, 
except for Ewing sarcoma and osteosarcoma [1]. Imaging 
evaluation of patient presenting with a vertebral tumor 
usually includes radiography, computed tomography (CT), 
bone scintigraphy and magnetic resonance (MR) imaging. 
CT is superior to conventional radiography for evaluat-
ing lesion location and analyzing tumor matrix and bone 
changes. Whole-body MR has been evaluated in vari-
ous oncologic indications [2]. MR has unmatched ability 
to assess extension to the bone marrow, soft tissue, and 
spinal canal and allows evaluation of treatment response. 
Technetium bone scintigraphy can be helpful in reveal-
ing an osseous lesion and to document multifocality [3]. 
Unfortunately, bone scintigraphy is nonspecific and often 
unable to help distinguishing between benign tumors, 
tumor-like conditions, and malignant tumors. The final 
diagnosis of spinal tumors is based not only on patient age, 
histologic features, and topographic features of the tumor 
(Figure 1), but also on analysis of the pattern on imaging. 
Table 1 summarizes the demographic data and localiza-
tion of most common  malignant primary tumors of the 
spine. The purpose of this article is to review the imaging 
features of the most  prevalent primitive malignant tumors 
of spine.
Osteosarcoma
Osteosarcoma is a primitive malignant bone tumor char-
acterized by the production of osteoid or immature bone 
from neoplastic cells [4]. Spinal osteosarcoma comprises 
3.6–14% of all primary spinal tumors and 4% of all 
osteosarcomas [5]. They occur in older age groups than 
osteosarcoma of the appendicular skeleton (mean age 
of 38 years), with a male predilection. In 79% of cases, 
the tumor arises in the posterior elements with partial 
vertebral body involvement. Involvement of two verte-
bral levels is seen in 17% of cases [5, 6]. Radiographs and 
CT usually show a mixed osteosclerotic-osteolytic lesion. 
A heterogenous soft tissue mass with ossified and non 
ossified components is commonly associated. Rarely, 
tumors with marked mineralization originating in the 
vertebral body may manifest as an “ivory vertebra” (scle-
rosing osteoblastic osteosarcoma). A purely lytic pattern 
is also seen in various subtypes such as telangiectatic 
osteosarcoma (predominant cystic architecture simulat-
ing aneurysmal bone cyst).
MR of spinal osteosarcoma is usually nonspecific. 
Mineralized component of the tumor shows low  signal 
on T1-weighted images (WI) and T2-WI, whereas the 
 nonmineralized component displays a high signal on 
T2-WI. Fluid-fluid levels have been described in  association 
with telangiectatic osteosarcoma [7]. Expansive  pattern 
cortical destruction, soft tissue extension, and  pathological 
 fractures may be seen [4].
Local recurrence is estimated at 20% after en bloc 
 excision and 60% after locoregional excision [4, 8].
Chondrosarcoma
Chondrosarcomas represent a heterogenous group of 
tumors characterized by their capacity of cartilage forma-
tion [9]. Chondrosarcoma accounts for 10% of all primary 
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bone tumors [10] and less than 12% may occur in the 
spine [11]. The thoracic spine is the most frequent locali-
zation (accounting for 60%), followed by the cervical and 
lumbar spine [12]. Spinal chordosarcoma may arise in the 
posterior elements (40%), in the vertebral body, or both 
[13]. Men are affected two or four times as much as women 
and the mean age of patients is 45 years [8].
Most lesions represent primary chondrosarcoma; how-
ever, secondary chondrosarcoma may also occur when 
osteochondroma (solitary or multiple with hereditary 
multiple exostoses) undergoes malignant transforma-
tion [8]. Radiographs demonstrate a well-defined mass 
with internal calcifications [13]. Chondroid matrix 
mineralization (Figure 2a) is better demonstrated by 
Figure 1: Drawing showing the common distribution of primary malignant tumors of spine. The brown line indicates 
the border between the vertebral body and posterior elements.
Table 1: Epidemiology of malignant primary tumors of the spine.
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CT, showing typical “rings and arcs” [14]. CT may dem-
onstrate a geographic osteolysis with sclerotic bor-
ders [1]. It may also allow evaluation of paravertebral 
extension of the tumor, the shifting and infiltration of 
surrounding structures, and involvement of adjacent 
levels. Involvement of adjacent vertebral levels by exten-
sion through the disk is seen in approximately 35% of 
cases, and adjacent ribs may be affected in thoracic 
neoplasms [8]. Occasionally, spinal chondrosarcoma 
may present as a lytic lesion involving the vertebral 
body or compression fracture of the superior or inferior 
end-plates [13].
On MR the tumor is of low signal on T1-WI (Figure 2c) 
and heterogeneous with areas of low and high signal inten-
sities on T2-WI (Figure 2b and 2d) and Short Tau Inversion-
Recovery (STIR) images, corresponding to mineralized and 
nonmineralized matrices. In addition, MR is superior to 
CT in depicting the epidural and intraforaminal extension 
highlighting possible compression of the neural structures. 
Fat-suppressed contrast-enhanced T1-WI show peripheral 
and lobulated rim enhancement (Figures 3e and 4d). 
Chondrosarcoma tends to recur if inadequately treated. En 
bloc resection provides the best chance of survival and the 
lowest rate of local recurrence [15].
Figure 2: Chondrosarcoma of T8, T9 and T10. (a) Axial CT scan shows a large mass arising from the vertebral body 
with ring-and-arc calcifications. MRI (b) coronal T2-WI, (c) Axial T1-WI and (d) Axial T2-WI show a heterogenous mass 
consisting of lobules of intermediate signal intensity on T1-WI with residual intralesional bony trabeculae and high 
signal on T2-WI sourrounded by hypointense ring-and-arcs.
Figure 3: Chondrosarcoma of C7. (a) Lateral radiograph of cervical spine shows a large iuxta-osseous calcified 
mass  arising from the vertebral body of C7 (arrow). (b, c, d, e) MR: Sagittal T1-WI, Sagittal T2-WI, Transversal T1-WI, 
 Transversal T1-WI after gadolinium contrast injection show lobulated mass of intermediate signal intensity on T1-WI 
and high signal intensity on T2-WI (arrows) with ring-and-arc enhancement (arrowhead).
Mechri et al: Imaging of Malignant Primitive Tumors of the SpineArt. 56, page 4 of 11 
Chordoma
Chordoma is a rare malignant neoplasm arising from 
the embryonic remnants of the primitive notochord 
and accounts for 2–4% of all primary malignant bone 
 neoplasm, with an estimated prevalence of 0.51 per 
 million. Chordomas generally occur in middle-aged 
patients, with a peak prevalence in the 5th–6th decades. 
Spinal chordomas have a 2:1 male–female ratio [16].
Eighty-five per cent of chordomas occur in spheno-
occipital skull base (35%), sacro-coccygeal area (50%) [17], 
and the vertebral bodies (15%). Spinal chordomas arise 
more frequently in the cervical spine than in the thoracic 
and lumbar regions [17]. This tumor may present a sig-
nificant variability in histology and is divided into three 
types: conventional, chondroid, and dedifferentiated [18]. 
Clinical manifestation is often subtle because chordomas 
are slow-growing lesions.
Radiographs and CT scan usually show a lytic lesion of 
a vertebral body associated with a soft-tissue mass with a 
“mushroom” appearance, spanning several segments and 
sparing the disks. Areas of amorphous calcifications are 
noted in 40% of chordomas of the mobile spine and in up 
to 90% of sacrococcygeal lesions [14]. Bone sequestra may 
be also seen. In some cases sclerosis predominates, leading 
to an “ivory” vertebral appearance, but this pattern is rare.
Chordomas show signal characteristics parallel to 
nucleus pulposus of the disk (notochord) on MR being 
low to intermediate signal on T1-WI (Figure 5a) and very 
high signal on T2-WI [19]. Coronal images on MRI demon-
strate a “mushroom” appearance of the tumor (Figure 5c). 
High signal intensity on T1-WI may be seen and due to 
focal areas of hemorrhage and high protein content of the 
myxoid and mucinous components. The fibrous septa that 
divide the gelatinous components of the tumor are seen 
as areas of low signal intensity on T2-WI [1]. The presence 
of hemosiderin also accounts for the low signal intensity 
seen on T2-WI. After injection of gadolinium contrast, 
most chordomas show moderate heterogeneous enhance-
ment (Figure 5b). Thick peripheral and septal enhance-
ment similar to chondrosarcoma may be seen [20].
Chordoma should be differentiated from giant embry-
onic remnants of the notochord (disappearing during the 
second month of embryonal life). Unlike in chordoma, 
radiographs and CT fail to demonstrate a distinct lesion 
in giant notochordal rest, instead showing either normal 
bone or a variable degree of sclerosis [1]. Bone scintigraphy 
is typically normal, whereas MR shows a lesion of low T1- 
and high T2-WI signal intensity and no soft-tissue involve-
ment. In doubtful cases, repeated CT scan or MRI imaging 
studies help ensure that the lesion is not progressive. 
Figure 5: Chordoma of L2. MR. (a) Axial T1-weighted, (b) axial T1-WI after gadolinium contrast injection, coronal 
T2-WI (c) show a lobulated mass lesion of heterogeneous signal originating from the vertebral body of L2 with large 
soft tissue component extending into the paravertebral muscles (curved arrow) and anterior epidural space (arrow).
Figure 4: Sacral chondrosarcoma. (a) Plain radiograph of pelvis shows an ill-defined osteolytic lesion of left sacrum 
(white arrow). (b) transversal CT scan shows extension through the left sacroiliac joint, the ilium and the gluteal 
muscles. (c, d) MR: transversal T2-WI, transversal T1-WI after gadolinium contrast injection show a lobulated mass 
predominantly of high signal intensity on T2-WI with ring-and-arc enhancement (arrowhead).
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When the tumor involves the sacral bone, the main dif-
ferential diagnoses are chondrosarcoma and metastasis 
[21]. The purely lytic lesions may mimic plasmocytoma. 
Osteomyelitis and lymphoma should also be considered.
Chordoma is a low-grade and slowly growing tumor but 
generally has a poor long-term prognosis. Metasases are 
rare, estimated between 4 to 43% of patients [8], but local 
recurrence is frequent.
Ewing Sarcoma and PNET
Ewing sarcoma and PNET are defined as round cell sar-
comas that show varying degrees of neuroectodermal 
differentiation [22]. Ewing sarcoma is the most common 
nonlymphoproliferative primary malignant tumors of 
the spine in children and adolescents. The peak of inci-
dence is usually seen in the second decade of life (mean 
age, 19.3 years), with a slight male predominance (62% vs 
38% of cases) [1]. Lesions of the spine account for 3–10% 
of all primary sites of Ewing sarcoma [1]. The most com-
mon location is the sacrococcygeal region, followed by 
the lumbar and the thoracic spine. Cervical spine involve-
ment is rare (3.2% of patients) [19]. In the nonsacral spine, 
most lesions (60%) originate in the posterior elements 
with extension into the vertebral body [1]. More than one 
 segment is involved in 8% of cases. The disk spaces are 
usually preserved [23].
Pain is the most common symptom of patients suf-
fering from spinal Ewing’s sarcoma [24]. Neurological 
deficit or radiculopathy is seen in 80% of patients [23]. 
Histologically, these tumors are composed of small round 
blue cells with large irregular sheets of cells divided by 
strands of fibrous tissue [25]. Several studies have con-
firmed a characteristic 11–22 chromosomal translocation 
in Ewing’s sarcoma in 85% of cases [26]. Lesions may be 
lytic (Figure 6a), sclerotic, or mixed. Almost all tumors 
(93%) are lytic and morphologically aggressive with large 
paraspinal soft tissue components that are usually larger 
than the intraosseous lesion. A purely sclerotic pattern is 
uncommon and may correspond to necrotic and reactive 
bone formation. Other unusual imaging findings include 
vertebra plana, ivory vertebra, and pseudohemangioma 
[27]. Invasion of the spinal canal is common (91% of cases) 
(Figure 6b and 6c).
The prognosis in Ewing sarcoma/PNET has improved in 
the modern era of treatment and current survival rate is 
estimated to be 41% [22]. The best therapeutic results are 
provided in radical resection and (neo-) adjuvant chemo-
therapy combined with radiation therapy [23].
Lymphoma
Lymphoma is categorized as primary osseous lymphoma 
if bone is the only known site of disease for six months 
[28]. It is a rare extranodal manifestation of non-Hodgkin 
lymphoma, accounting for only about 1%–3% of all lym-
phomas and 7% of primary bone tumors [29]. Patients are 
between 40 to 60 years old with an equal male to female 
ratio [23]. In most cases, lymphoma involves the anterior 
vertebral column, whereas posterior involvement is rare.
Figure 6: Ewing Sarcoma of L3. (a) Plain radiograph of lumbar spine reveals lytic lesion of right pedicle and right 
transverse process with partial vertebral collapse (arrow). (b, c, d) MR: coronal T2-WI, sagittal T2-WI and T1-WI after 
gadolinium reveal vertebral lesion of L3 with high signal intensity on T2-WI, enhancing after gadolinium injection 
and extending to prevertebral muscles (arrowhead) and to epidural space (arrow).
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Histologically, most bony lymphomas show a mixed 
cell infiltrate in which the cellular size and shape differ 
considerably. The very characteristic infiltrative pattern 
should suggest the diagnosis of lymphoma. The medullary 
bony trabeculae may show reactive sclerosis [23].
Radiologically, the lesions are lytic (Figure 7), mixed, or 
rarely sclerotic causing ivory vertebra. Lymphoma should 
be considered in the differential diagnosis of any sclerotic 
vertebral lesion. Bony sequestra may be seen as well. MR 
is helpful to detect bone marrow involvement, and large 
soft tissue component appearing as areas of low signal 
intensity on T1-WI (Figure 8a) and hyperintense on T2-WI 
(Figure 8b) and variable enhancement. MR may also 
show a pathological fracture. Patterns of focal/multifocal 
uptake of 18F-FDG on a background of diffuse uptake at 
FDG PET/CT should be considered positive for bone mar-
row involvement. On the other hand, a completely diffuse 
(nonfocal) pattern of 18F-FDG uptake is nonspecific and 
may represent hematopoietic response to cytokines, espe-
cially after onset of treatment [28].
The treatment options of the primary bone lympho-
mas are surgical, chemotherapy, and radiotherapy [30]. 
Isolated spinal lymphoma responds very well to chemo-
therapy and radiotherapy. Lesions causing compression 
or complicated by pathological fracture with neurological 
deficits may require surgical decompression and stabili-
zation using an anterior approach primarily followed by 
chemotherapy and radiation therapy.
Plasmocytoma
Plasmocytoma (Figure 9) is a clinical variant considered to 
represent an early stage of multiple myeloma, with stages 
of transition existing between the localized and the dis-
seminated types [31]. It is an uncommon tumor occuring 
in 3–7% of patients with plasma cell neoplasms. Seventy 
percent of patients are over 60 years old [1], but it has also 
Figure 7: Lymphoma of the sacrum. Axial CT scan image shows a destructive lesion of sacrum extending through the 
left sacroiliac joint (arrowhead).
Figure 8: B-cell lymphoma of L2. MR: (a) Sagittal T1- and (b) T2-WI image show an osseous lesion of L2 (white arrow) 
extending into spinous process of L1 and L2 and in the posterior epidural spaces (black arrow) but without extension 
through the intervertebral disk.
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been reported in adolescents [32]. A monoclonal immuno-
globulin is present at a low seric level in 40% of cases [1].
The most common symptom is local pain in the region 
of the affected spine, radicular pain or neurological deficit.
The spine is involved in 25–50% of the cases. Thoracic 
vertebrae are most commonly involved [33]. The male 
to female ratio is 2 to 3/1 [23]. The vertebral body is the 
most common site of involvement by plasmocytoma due 
to its rich red marrow content, but the tumor frequently 
extends to the pedicles [1]. Plain radiographs show a soli-
tary radiolucent lesion within the axial skeleton or a high 
loss of vertebral body. Technetium bone scan is  normal, 
except in case of a pathological fracture.
The treatment of choice is chemotherapy and/or radia-
tion therapy at 40 Gy to 50 Gy [35]. Solitary plasmocy-
toma usually progresses to multiple myeloma in three 
to five years [34]. Surgery is performed for decompres-
sion and stabilization of the spine in case of pathological 
fracture, kyphosis, neurological deficit, or pain caused by 
instability [23].
Multiple Myeloma
In 2014, the International Myeloma Working Group 
(IMWG) revised diagnostic criteria for multiple myeloma 
(MM), allowing the use of specific biomarkers and mod-
ern imaging tools to define the disease in addition to the 
established CRAB features [35]. Multiple myeloma is the 
third most common blood cancer in adults, with a reported 
prevalence of 4.3 cases per 100,000 population [36].
Skeletal involvement occurs in 80–90% of patients with 
MM [37]. Vertebral involvement is observed in 65% of 
cases [38]. Multiple myeloma can affect any bone, includ-
ing the skull, spine, pelvis, ribs, and proximal long bones. 
Therefore, a complete skeletal survey should include 
a postero-anterior and lateral view of the skull, spine, 
humeri, and femora, as well as an antero-posterior view of 
the pelvis and chest [39]. Radiographic findings of multi-
ple myeloma include focal well-circumscribed lytic lesions 
without surrounding reactive sclerosis (70% of cases) [38] 
(Figure 10) or diffuse osteolysis [40]. Sclerotic lesions are 
less common and should raise the suspicion of POEMS syn-
drome (Polyneuropathy, Organomegaly, Endocrinopathy, 
M-protein and Skin changes) [41].
Ten to 20% of patients with multiple myeloma are 
 normal on radiography [42, 43]. Pathological  compression 
fractures of the vertebral bodies related to  osteopaenia 
and/or lytic lesions (Figure 10) are common. Bone 
 scintigraphy is not useful for the assessment of therapy.
Although new or enlarging lesions generally mean dis-
ease progression, lytic bone lesions rarely show evidence 
of healing on plain radiographs, and routine follow-up 
skeletal survey is of no benefit [44].
Whole-body multidetector computerized tomography 
(WB-MDCT) is a preferable imaging tool over whole-body 
X-ray (WBXR) surveys for assessment of fracture risk and 
characterization of compression fractures [45]. Limitations 
of WBCT are a higher radiation [39], a limited evaluation 
of intramedullary bone invasion without cortical bone 
involvement leading to understaging, lack of specificity in 
evaluating osteopenia [46], and inability to assess response 
to therapy. Similar to WBXR, osseous lesions can remain 
unchanged on WBCT even after complete remission.
MR in patients with clinical and laboratory findings of 
symptomatic myeloma provides prognostic information 
and may detect unsuspected myeloma lesions [44]. Five 
different infiltration patterns can be differentiated on 
MR: normal appearance of bone marrow despite minor 
microscopic plasma cell infiltration, focal involvement, 
homogeneous diffuse infiltration, combined diffuse 
and focal infiltration, and “salt-and-pepper” pattern with 
inhomogeneous bone marrow with interposition of fat 
islands [47]. Typical MM lesion is hypointense on T1-WI 
Figure 9: Sacral plasmocytoma. MR: (a) Sagittal T1-WI shows homogenous mass involving S1, S2 and S3 with 
 intermediate signal intensity. (b) Sagittal T2-WI show a high signal intensity of the mass extending into the pelvis, 
epidural space, and posterior elements.
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(Figure 11a) and of moderate increased signal on T2-WI s 
(Figure 11c). However, due to the high signal intensity of 
normal bone marrow on T2-WI, fat suppression is required 
for a more sensitive detection rate. Contrast administra-
tion is not necessary routine, but shows enhancement of 
the lesion (Figure 11b); an enhancement greater than 
40% is considered pathologic [48].
Abnormal signal can also be observed after chemother-
apy and the use of growth factors or in young individu-
als with hyperplasia of normal haematopoiesis. Thus, the 
Figure 10: Multiple myeloma. Plain radiograph of spine shows an osteolytic lesion with cortical breakthrough, 
 vertebral collapse and soft tissue mass (arrow).
Figure 11: Multiple myeloma. MR: (a) Sagittal T1-WI, (b) sagittal fat-suppressed T1-WI after gadolinium contrast 
administration and (c) sagittal fat-suppressed T2-WI of the thoracolumbar spine display a diffuse bone marrow 
 infiltration of vertebrae with low signal intensity on T1-WI and intermediate to high signal intensity on T2-WI. 
There is multifocal enhancement. 
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clinical context should be taken into account when evalu-
ating MR, and MR should not be performed close to chem-
otherapy. Diffuse marrow infiltration has a decreased 
signal on T1-WI and an increased signal on STIR. The over-
all performance of MR is enhanced by applying dynamic 
contrast-enhanced MR and diffusion-weighted imaging 
sequences, providing additional functional information 
on bone marrow vascularization and cellularity [48].
Posttreatment MRI typically demonstrates a gradual 
replacement of marrow infiltration or focal lesions by 
marrow fat, but this may be delayed up to four or five 
years in some focal lesions [44].
FDG PET/CT is particularly sensitive for the detec-
tion of extramedullary disease and can help detect the 
 metabolically active lesions that often precede evidence 
of osseous destruction at conventional radiography [49]. 
Both MR and FDG PET/CT allow accurate localization 
of disease after chemotherapy or autologous stem cell 
 transplantation and can provide important prognostic 
information that can influence further clinical decision 
making regarding therapy, particularly when tumor serum 
markers may be a less reliable indicator of disease burden 
after repeated treatment [49].
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